fda bans tirzepatide says 'no clinical need' for compounded weight loss drugs 2026 FDA Rules and News

Weight loss with semaglutide is typically progressive, with most patients losing approximately 15% of body weight over 68 weeks at the 2.4 mg dose in clinical trials

If structured nutrition, fitness, or behavior support matters, Henry Meds or MEDVi build that into the offering

Women, on the other hand, generally have lower baseline creatine stores and tend to do well with a lighter daily dose, and some research points to added benefits around hormonal fluctuations

When your provider can cite both clinical assessment and genetic predisposition data, the medical necessity argument becomes more robustpotentially supporting your reimbursement request and ensuring you receive treatment tailored to your biology